Publication | Open Access
Depletion of the ER chaperone ENPL-1 sensitizes<i><i>C. elegans</i></i>to the anticancer drug cisplatin
17
Citations
34
References
2013
Year
Cisplatin SensitivityMolecular BiologyAnticancer Drug CisplatinEr StressTumor BiologyEr Chaperone Enpl-1Transcriptional RegulationSignaling PathwaySecretory PathwayCell SignalingCancer ResearchCellular BiologyEr Stress LevelsGene ExpressionCell BiologySignal TransductionNatural SciencesTumor SuppressorCellular BiochemistrySystems BiologyMedicine
Cisplatin is an essential chemotherapeutic drug in the treatment of many cancers. Its use, however, is limited by the development of resistance in many tumors. The ability to re-sensitize resistant tumors could significantly strengthen cisplatin therapy in patients. Caenorhabditis elegans is a suitable model for studying the cytoplasmic role of cisplatin in tumor cells. We have previously shown that the ATPase ASNA-1 has similar roles as a factor governing cisplatin sensitivity in mammalian tumor cells and C. elegans. Here we study the endoplasmic reticulum (ER) resident chaperone ENPL-1/GRP94 and find that its depletion makes worms sensitive to cisplatin. Elevated ER stress levels in enpl-1 mutants is the likely cause of this sensitivity because a correlation can be made between cisplatin sensitivity and the high ER stress levels. We also find that asna-1 mutants have elevated unfolded protein response (UPR) activity and that the intrinsically cisplatin resistant wild-type worms become sensitive when ER stress is high. We conclude that enpl-1 is a cisplatin sensitizing factor and suggest that manipulation of its levels or of UPR activity will enhance the effects of cisplatin based cancer therapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1